Joined in 2023 
82 
63 About this deal
We identified 3 studies in this review that showed a decline in urine lead and cadmium levels following treatment with EDTA, although statistical significance was only tested and confirmed in 2 studies. Furthermore, phosphatidylcholine is well-established in the medical literature for its essential role in the formation and repair of cellular membranes and contributions to overall cellular health. It also plays a significant role in metabolism, nerve signaling, and liver function. What are the Benefits of Plaquex Therapy? As we get older, our body’s repair systems don’t work as well because we can’t produce enough of a substance called phosphatidylcholine. This makes our cell membranes less flexible, causing enzymes, electrolyte channels, and receptors to malfunction. As a result, our blood vessels can get damaged, leading to scar tissue, plaque buildup, and even blood clots. Measures of association and CIs were extracted or derived from the eligible studies. For all studies, except Lamas et al and Green et al, the total mean change was selected as the measure of association for comparison in continuous outcomes. A third study measured urinary lead and cadmium immediately pretreatment and posttreatment at baseline and after the final infusion. After the first infusion, both urinary lead and cadmium significantly increased by 22.4μg/g creatinine (SD, 15.17μg/g creatinine) and 3.0μg/g creatinine (SD, 1.59μg/g creatinine), respectively. The corresponding increases following the last infusion were 7.2μg/g creatinine (SD, 5.69μg/g creatinine) for lead and 3.4μg/g creatinine (SD, 1.94μg/g creatinine) for cadmium.
Plaquex increases the levels of Glutathione and Sodium Oxide Dismutase by increasing the enzymes in the cell membranes responsible for these antioxidants. It thereby combats lipid peroxidation and prevents alcohol induced liver fibrosis by inhibiting alcohol induced oxidative stress. 55-57 A formal study called the TACT clinical trial was a randomized controlled trial that investigated the effect of disodium EDTA chelation therapy on cardiovascular events in patients with a history of myocardial infarction (MI). Please note that these patients had all suffered a significant event already, and while chelation therapy was still shown to be beneficial, we like to see patients take a proactive approach and use chelation proactively before an event occurs. EDTA chelation therapy for stable ischemic heart disease was classified as a IIB treatment with level B evidence in the 2014 American College of Cardiology/American Heart Association/American Association for Thoracic Surgery/Preventative Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, suggesting that although treatment may outweigh risk, further investigation is necessary to recommend routine use. were included (Tables 2 and and3). 3). The sample size of the RCTs ranged from 32, in a single‐center study conducted in New Zealand, to 1708, in the TACT, a multicenter clinical trial conducted across the United States and Canada. The sample size of prospective before/after studies ranged from 8 in an Australian study conducted in patients with coronary artery disease (CAD) to 132 in a study conducted in patients with angina pectoris, intermittent claudication, or some form of cerebrovascular disease. The sample size of the retrospective case series studies ranged from 4, in a qualitative study of patients with end‐stage occlusive PAD, to 2870, in a retrospective study of patients at a private clinic in Brazil. Five additional publications reporting different results from the same study population as the initial publication were also summarized in the tables, 3 of them related to the TACTEarly practitioners proposed decalcification of atherosclerotic plaque as a possible mechanism for EDTA benefit. Although EDTA benefit in atherosclerotic disease is not standard of care, more recent investigations suggest that benefits of chelation may stem from removal of established cardiotoxic metals, such as lead or cadmium. Plaquex transforms cholesterol, including plaque deposits, enabling HDL to take it up and remove it from vascular walls, and eliminate it through the liver. Plaquex Therapy for Liver Damage Liver damage always involves cell membrane damage, and Plaquex can help restore cell membranes and cell function by providing exogenous phosphatidylcholine (PC). Plaquex therapy is also used to treat Atherosclerosis and is given to patients suffering from angina pectoris whose coronary arteries contain plaque deposits, but also in patients with carotid artery plaque and peripheral plaque in the legs, causing claudication pain when walking. It is also used to improve the function of the liver and kidneys, skin texture, and gut lining. How is Plaquex Therapy Administered?
Given the prolonged timespan during which the extracted studies were conducted, numerous EDTA infusion regimens were used. Each infusion regimen used different minerals, EDTA salt, and EDTA dosage, resulting in a potential source of confounding for comparison between studies. Most studies (n=17) reported using Na 2EDTA as the chelating agent, with only one study using calcium Na 2EDTA. Similarly, dosage varied across studies, as some reported using a fixed EDTA dose for all patients, whereas others adjusted chelating agent dose based on body weight or glomerular filtration rate. No clear pattern emerged between EDTA dosage and patient improvement. Choice of minerals and amount of water present in the infusion may also have had a confounding effect. In studies examining renal function, a high amount of saline in the solution may have helped improve dehydrated patients, rather than EDTA chelation. Two studies that reported improved renal function did not indicate the solution components, but the improvement may have been related to the volume of crystalloid infused.Salvioli, G. Scand J. Gastroenterology 12 (1977) 841-847 Salvioli, G. et al. Gut 19 (1978) 844-850 Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99
During Plaquex Infusion therapy, phosphatidylcholine is injected directly into the bloodstream through an IV. The infusion typically takes around 90 minutes to complete, and patients may undergo several sessions over the course of several weeks or months. A total of 24 studies, extending from 1957 to 2019, met the inclusion criteria, including 6 studies found by hand search. Of these, 4 RCTs (Table 1), Grebenev, A.L., S.S. Katsev, V.S. Golochevskaja, L.P. Geniya: Lipostabil in the treatment of hyperlipidemia and the possibility of its correcting effect on liver fu Three studies evaluated quality of life with the 36‐Item Short Form Health Survey and/or the Duke Activity Status Index (Table 6).The before and after testing needs to be done with the same equipment and software, eg. Calcium Score scanner. Arsenio, L., P. Bodria, G. Magnati, A. Strata: Studio dell' attivita terapeutica della fosfatidilcolina in diabetici con associata iperdislipidemia. Clin. Ter. 114 (1985) 117-127 A subset of the PATCH study also found no difference in brachial artery diameter between chelation or placebo treatment.
TACT also suggested, in a nonprespecified analysis, that post–myocardial infarction patients with PAD as well as underlying diabetes improved significantly (HR, 0.52; P=0.0069). Similarly, cadmium has also been associated with reduced glutathione activity, cadmium‐induced cell death through apoptotic pathway activation, and DNA methylation, resulting in increased oxidative stress, inflammation, and endothelial cell death.
Preparing for Plaquex Therapy
Influenza della somministrazione di EPL sulle variazioni delle HDL2 e HDL3. Round Table Phospholip. Atheroscleros. Rome, Nov. 1984
Great Deal 
New Comment